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Evaluation of biolistic gene transfer methods in
vivo using non-invasive bioluminescent imaging
techniques
Jixiang Xia, Angela Martinez, Henry Daniell and Steven N Ebert*
Abstract
Background: Gene therapy continues to hold great potential for treating many different types of disease and
dysfunction. Safe and efficient techniques for gene transfer and expression in vivo are needed to enable gene
therapeutic strategies to be effective in patients. Currently, the most commonly used methods employ replication-
defective viral vectors for gene transfer, while physical gene transfer methods such as biolistic-mediated ("gene-
gun”) delivery to target tissues have not been as extensively explored. In the present study, we evaluated the
efficacy of biolistic gene transfer techniques in vivo using non-invasive bioluminescent imaging (BLI) methods.
Results: Plasmid DNA carrying the firefly luciferase (LUC) reporter gene under the control of the human
Cytomegalovirus (CMV) promoter/enhancer was transfected into mouse skin and liver using biolistic methods. The
plasmids were coupled to gold microspheres (1 μm diameter) using different DNA Loading Ratios (DLRs), and
“shot” into target tissues using a helium-driven gene gun. The optimal DLR was found to be in the range of 4-10.
Bioluminescence was measured using an In Vivo Imaging System (IVIS-50) at various time-points following transfer.
Biolistic gene transfer to mouse skin produced peak reporter gene expression one day after transfer. Expression
remained detectable through four days, but declined to undetectable levels by six days following gene transfer.
Maximum depth of tissue penetration following biolistic transfer to abdominal skin was 200-300 μm. Similarly,
biolistic gene transfer to mouse liver in vivo also produced peak early expression followed by a decline over time.
In contrast to skin, however, liver expression of the reporter gene was relatively stable 4-8 days post-biolistic gene
transfer, and remained detectable for nearly two weeks.
Conclusions: The use of bioluminescence imaging techniques enabled efficient evaluation of reporter gene
expression in vivo. Our results demonstrate that different tissues show different expression kinetics following gene
transfer of the same reporter plasmid to different mouse tissues in vivo. We evaluated superficial (skin) and
abdominal organ (liver) targets, and found that reporter gene expression peaked within the first two days post-
transfer in each case, but declined most rapidly in the skin (3-4 days) compared to liver (10-14 days). This
information is essential for designing effective gene therapy strategies in different target tissues.
Keywords: Bioluminescence, Gene Therapy, Biolistic, Mice, Imaging, Non-invasive
Background
Gene therapy is a promising strategy for correcting both
genetic and acquired diseases [1,2]. There are a variety
of gene delivery methods currently available, with the
main purpose of any given strategy being to efficiently
transfer and express the target gene(s) of interest
without adverse side-effects. Development of improved
gene delivery strategies is critical for application of
effective gene therapies, yet evaluation of the effective-
ness of these strategies is often hampered by difficulties
in detecting transgene expression in real-time in vivo.
Non-invasive bioluminescent imaging (BLI) has been
successfully used for evaluation of cell and gene thera-
pies in small animal models [3-6], though it has not yet
been systematically applied to analysis of physical gene
* Correspondence: ebert@mail.ucf.edu
Burnett School of Biomedical Sciences, University of Central Florida College
of Medicine, Orlando, FL 32827 USA
Xia et al. BMC Biotechnology 2011, 11:62
http://www.biomedcentral.com/1472-6750/11/62
© 2011 Xia et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
transfer methods. The purpose of the present study is to
evaluate the effectiveness of biolistic gene transfer in dif-
ferent types of tissue in mice using non-invasive in vivo
bioluminescence imaging (BLI).
Vectors for gene delivery can be divided into two gen-
eral categories: viral and non-viral. Viral vectors are
widely employed for gene therapy as they are highly effi-
cient, and the effects can be sustained over periods of
weeks, months, and sometimes years [7,8]. A number of
different viral vectors have been utilized for gene ther-
apy approaches based on cell/tissue-type preferences.
Some of these include adeno- and adeno-associated
virus, herpes virus, retrovirus, and lentivirus, among
others [7,8]. Each has its own advantages and disadvan-
tages depending on application and tissue type. In gen-
eral, recombinant replication-defective (ie, crippled) viral
vectors are used for this purpose to minimize threats of
infection, immune responses, and other potentially
adverse conditions. In the past, serious consequences
have resulted from the use of viral vectors for gene ther-
apy in humans [9,10]. Most notably, the death of 18-
year old Jesse Gelsinger due to immune complications
arising in response to adenovirus vectors essentially
halted clinical trials using viral vectors for gene therapy
for many years [11-13]. More recently, other viral vec-
tor-based gene therapy approaches have come into
question because of associated genomic instability and
activation of proto-oncogenes [14,15]. Thus, it is becom-
ing increasingly clear that there is an inherent risk of
serious adverse side effects with some viral-based gene
therapy strategies.
Alternatively, non-viral gene therapy strategies pose
less risk of infection and/or adverse immune responses.
Non-viral gene transfer techniques typically involve
either chemical or physical methods. Chemical methods
such as calcium-phosphate or liposome-based
approaches have achieved much success for in vitro
applications in cell cultures, but have been of more lim-
ited utility in vivo due to low transfection efficiencies
and toxicity issues [16-18]. Physical methods are diverse
and include direct injection of DNA, electroporation,
ultrasonic-based, and biolistic approaches in addition to
a variety of other techniques [16-18]. In most cases
where chemical or physical methods are employed, puri-
fied plasmid DNA is used for delivery. When effective,
this typically results in transient expression in target tis-
sues since the “naked” DNA is eventually degraded by
host nucleases [19]. Thus, these methods are currently
limited to specific applications where transient expres-
sion of a transgene is warranted (e.g., induction of
angiogenesis) [20-23].
In the present study, we chose to use physical meth-
ods of gene transfer to avoid the complications asso-
ciated with viral and chemical strategies. In particular,
we explore the use of biolistic methods of gene transfer
due to its widespread applicability and low toxicity. Bio-
listic gene transfer has been used for many years pri-
marily for the study and production of transgenic plants
[24-27]. It is, in fact, the preferred and most commonly
used method for gene transfer in plants due to its versa-
tility and effectiveness. Due to their tough outer cell
walls, plants typically require helium pressures well in
excess of 1000 pounds/square inch (psi), and the proce-
dure is usually performed under vacuum using a station-
ary biolistic gene delivery chamber. Animal cells, in
contrast, cannot tolerate bombardment with such high
pressure, nor are they amenable to vacuum conditions
for the transfer process. In recent years, however, a
hand-held device known as the Helios™ gene gun (Bio-
Rad Labs, Hercules, CA) has been developed for biolistic
gene transfer experiments in animals using lower helium
pressures (≤ 600 psi) [28]. No vacuum is required, and
the DNA-gold particles can be delivered from a hand-
held gun that can be used to target virtually any tissue
or organ for direct biolistic gene transfer. This device
has been used to successfully perform biolistic gene
transfer in a number of mammalian cell-culture and
live-animal models [29-33]. In the current report, we
use BLI to evaluate the effectiveness of gene transfer via
biolistic techniques in vitro and in vivo.
Methods
Gene Gun Materials
The hand-held Helios Gene Gun, Tubing Prep Station,
Optimization Kit (including gold microcarriers, polyvi-
nylpyrrolidone or PVP, and tubing), and related supplies
were obtained from Bio-Rad, Inc. (Hercules, CA).
Reagents
Human embryonic kidney (HEK) 293 cells and mouse
embryonic stem cells were maintained as previously
described [6,34]. Cell culture reagents including Dulbec-
co’s Modified Eagle Medium (DMEM) and supplements
were obtained from Invitrogen, Inc. (Carlsbad, CA).
Fetal bovine serum was purchased from Hyclone Labs
(Logan, UT). Lipofectamine 2000 and XGAL were
obtained from Invitrogen, Inc (Carlsbad, CA). Luciferin
for in vivo use was obtained from Caliper Labs (Hopkin-
ton, MA). Bright-Glo™ Luciferase Assay Kit for in vitro
assays was supplied by Promega (Madison, WI). All
other chemicals and other reagents used in this study
were obtained from Sigma-Aldrich (St. Louis, MO).
Plasmids
Plasmids used in this study included pCMV-LUC (Clon-
tech, Menlo Park, CA), pNCX1-LUC [35], and pCMV-
beta-galactosidase (pCMV-bGal) [36] have been
described previously as indicated. All plasmids were
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purified using Qiagen Maxi-Prep DNA purification kits
(Valencia, CA) followed by phenol:chloroform:isoamyl
alcholol (25:24:1) extraction, ethanol precipitation, 70%
ethanol wash and air-drying. The dried pDNAs were
then resuspended in Tris-EDTA (TE, pH 8.0) buffer at a
concentration of 1 mg/ml. We found that the additional
organic extraction and ethanol precipitation/washing
steps were critical for achieving efficient coupling of
pDNAs to gold microcarriers.
Animals
Adult white FVB mice (18-25 g each) were used for this
study. The mice were housed in the Transgenic Animal
Facility at the University of Central Florida (UCF) on a
12:12 hr light:dark cycle, and provided food and water
ad libitum. All procedures utilizing mice in this study
were performed in accordance with approved UCF
IACUC protocols consistent with NIH regulations gov-
erning vertebrate animal research.
Preparation of gold microcarrier-coated cartridges
Preparation of gold microcarrier-coated cartridges was
performed according to the manufacturer’s instructions
(Bio-Rad, Inc., Hercules, CA) as previously described
[31,37]. Briefly, 25 mg of gold microcarriers (1 μm dia-
meter average size) were suspended in absolute ethanol
containing 0.05 M spermidine. An equal volume of
pDNA was added to this mixture, vortexed, and soni-
cated. Various amounts of pDNA were used to evaluate
different DNA-loading ratios (DLRs). By definition, DLR
of 1 = 1 μg DNA per mg of gold microcarrier particles
[37]. An equal volume of 1M CaCl2 was added to the
mixture in dropwise fashion, and then precipitated at
room temperature for 5 min (the volume of spermidine
was always the same as those of plasmid and CaCl2).
The solution was microcentrifuged (14,000 ×g) for 5s
and the supernatant was removed. The resulting pellets
were resuspended with 100% ethanol and washed three
times with same for 15s each. Finally, the pellets were
each resuspended in 2.5 ml absolute ethanol containing
0.05% polyvinylpyrrolidone (PVP), and sonicated to
achieve uniform suspension of microcarrier particles
prior to cartridge loading. Cartridge tubing was loaded
into the Bio-Rad Tubing Prep Station, dried with nitro-
gen gas, and coated internally with the microcarrier sus-
pension during continuous rotation of the tubing. After
complete drying, the tubing was cut into 0.5 inch car-
tridge “bullets” using the supplied tubing cutter, and
stored in the parafilm-sealed containers at 4°C until
ready for use.
Electrophoresis of microcarrier mixtures
Just before the last centrifugation step to concentrate
the microcarriers in absolute ethanol (see preceding
paragraph), a portion of the suspension was transferred
to microcentrifuge tubes, and dried in a Speed-Vac cen-
trifuge (Savant Instrument Inc, Farmingdale, NY). The
pellet was resuspended in electrophoresis loading buffer
and immediately subjected to electrophoresis in 0.8%
agarose gels containing 0.2 μg/ml ethidium bromide.
Each well was loaded with approximately equal amounts
of microcarriers. The gels were imaged under ultraviolet
light.
In vitro gene delivery
For biolistic delivery of reporter genes, cells were trypsi-
nized and transferred to six well plates and kept until
80% confluence prior to gene transfer. Immediately
before transfection, the medium was gently removed
and washed once with PBS, the barrel ring of hand held
gene gun was centered at the well and the distance to
the cells was about 2 cm. Upon pulling the trigger, the
gold microcarriers were shot out of the cartridges by
helium with pressures between 100-150 psi (1psi = 6.89
kPa). Fresh growth media was added to the dishes and
the cells were recovered in the incubator for another 48
h before bioluminescence measurement. As a positive
control, some wells were transfected in parallel using
lipofectamine according to the manufacturer’s instruc-
tions (Invitrogen, Inc.; Carlsbad, CA).
In vivo gene delivery
Mouse skin and liver were chosen as the targets of bom-
bardment for dynamic gene expression observation.
Prior to the procedure, the mice were administered with
2% isoflurane to achieve a surgical plane, and main-
tained as such using a nose-cone for continuous isoflur-
ane delivery (in oxygen, flow speed = 1L/min). The mice
were placed in supine position on a surgical pad, and
the abdominal hair was removed by Nair® hair-removal
lotion. For biolistic transfer to skin, the barrel ring of
the Gene Gun was lightly touching the skin. For biolistic
transfer to liver, an abdominal incision was made to
expose the organ, and the barrel of the Gene Gun was
positioned directly above the target. Following biolistic
delivery, the incision was sutured, and the mice were
administered buprenorphine (0.05 mg/kg) in the thigh
muscle to help mediate pain or discomfort associated
with the procedure. The mice were then removed from
anesthesia, returned to their cages, and were ambulatory
within a few minutes.
To determine if differences of DLR could affect
expression of biolistically-transferred genes, the mice
were divided into four groups with six mice per each
group, and DLR was varied between 0, 4, 10 and 25.
Helium pressure was set to 200 psi, and the microcarrier
bombardment was targeted to abdominal skin. In a sub-
sequent series of experiments, the helium pressure was
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adjusted to 300-400 psi for biolistic delivery to mouse
skin since the lower pressure (200 psi) was well-toler-
ated in the initial group. For biolistic transfer to soft tis-
sue (liver), helium pressure was held at a maximum of
200 psi to minimize tissue damage.
Bioluminescence imaging (BLI)
For in vitro BLI, luciferase assays were performed as
previously described [36] except that the results were
quantified using an In Vivo Imaging System-50 (IVIS-
50) from Caliper Labs (Hopkinton, MA). For in vivo BLI
assessment, mice were injected i.p. with D-luciferin
potassium salts (Caliper Life Sciences, Hopkinton, MA)
at a dosage of 150 mg/kg, and maintained for 5 min
before imaging. The mice were then anesthetized with
2% isoflurane and placed in the IVIS-50 chamber in
supine position where they were maintained with iso-
flurane administered through nose-cone ports inside the
chamber. The chamber temperature was kept constant
at 37°C throughout the procedure. Light emission was
collected for 5 min, and the intensity was represented as
the number of photons per second/cm2/steradian for a
designated “Region of Interest” or “ROI”. A standard
“ROI” template was used for each experiment so that
direct comparison of different data sets could be readily
managed. Images were processed using Living Image®
software (Caliper Life Sciences, Hopkinton, MA).
XGAL histological staining
Following biolistic transfer of pCMV-bGAL to mouse
skin as described above, mice were sacrificed three days
later by decapitation while under full anesthesia (2% iso-
flurane). The abdominal skin surrounding the biolistic
target area (22 mm diameter) was excised and fixed
with 4% paraformaldehyde for 1-2 hrs on ice. The tissue
was then transferred to a solution of 30% sucrose in
PBS and kept at 4°C overnight. The skin was sectioned
transversely (14 μm/section) using a cryostat instrument.
The protocol for the XGAL staining with acidified eosin
counterstaining was performed as described previously
[38].
Statistical analysis
Results are expressed mean values ± standard deviation.
One-way analysis of variance was used to determine if
statistically significant differences occurred, with p <
0.05 required to reject the null hypothesis.
Results
Our initial experiments were designed to test the func-
tionality of the biolistic gene transfer and BLI methods.
To accomplish this, we bombarded two different cell
types in culture with gold (Au) particles coated with or
without LUC reporter plasmid DNAs driven by different
promoters. As shown in Figure 1A, HEK cells blasted
with gold particles coated with pCMV-LUC produced a
strong bioluminescent signal in the presence of the luci-
ferin substrate. In contrast, cells blasted with gold parti-
cles alone (Au) or coated with LUC reporter plasmids
driven by the cellular promoter from the sodium-cal-
cium exchanger 1 (NCX1) gene generated no measur-
able bioluminescent signal. In parallel, we performed an
analogous transfection experiment using an established
in vitro transfection method using lipofectamine [39].
The results were similar to those achieved with the bio-
listic method except that CMV-LUC activity was much
more robust in the lipofectamine sample compared with
the biolistic sample in HEK cells. In contrast, biolistic
gene transfection produced brighter bioluminescence
than lipofectamine for CMV-LUC in mES cells (Figure
1C and 1D). The pNCX1-LUC construct did not pro-
duce measurable bioluminescence when transfected by
either method, and thus was not explored further in this
study.
To perform biolistic transfer of LUC reporter plasmid
DNA in vivo, we next evaluated the effectiveness of phy-
sical coupling of plasmid DNA to gold microcarrier par-
ticles. The gold microcarriers were 1 μm in diameter,
on average, and increasing DNA loading ratios (DLRs)
were evaluated by agarose gel electrophoresis. As shown
in Figure 2A, increasing the amount of pCMV-LUC in
the coupling reactions led to greater retardation of the
plasmid through the gel, thereby indicating that more of
the plasmid DNA was being coupled to the microcar-
riers. As the DLR increased from 4 to 10 or 25, how-
ever, increased amounts of uncoupled plasmid were
observed ("supercoiled” and “relaxed” bands, arrows, Fig-
ure 2A), possibly indicating that some saturation of
binding had occurred. When the DLR was increased
from 10 to 25, most of the plasmid did not enter the gel
presumably because higher order DNA-gold coupling
had occurred such that the complexes were now too
large to enter the gel. Less of the “free” supercoiled and
relaxed plasmid DNA was present with a DLR of 25
compared to that observed with a DLR of 10. Macro-
scopic inspection revealed some “clumping” of gold par-
ticles at the highest DLR of 25, which is consistent with
the idea that higher order coupling likely occurred in
this group.
To evaluate the efficacy of these different DLRs for
biolistic gene transfer, we employed the Helios gene gun
to deliver the gold microcarriers into mouse skin in
vivo. Reporter gene expression from the pCMV-LUC
vector was then measured using BLI. Quantitative ana-
lyses of these results are shown in Figure 2B. Expression
appeared highest 24 h after biolistic delivery, and then
declined steadily over the next few days. Surprisingly lit-
tle difference was observed with the different DLRs.
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Representative images of in vivo BLI for mice in these
experiments are shown in Figure 2, panels C-F. In the
absence of plasmid DNA, no BLI was apparent (DLR =
0, Figure 2C). In contrast, the BLI results for panels D-F
(Figure 2) showed similar levels of bioluminescence
activity under the conditions used for these experiments.
No significant differences in bioluminescence were seen
using microcarriers with DLRs = 4, 10, and 25, though
there was a trend towards increased bioluminescence
with increasing DLR after day one.
To maximize gene transfer effectiveness and consis-
tency, we chose the middle DLR of 10 to compare the
efficacy of biolistic gene transfer into different tissue
types in vivo. In this series of experiments we used BLI
to measure reporter gene activity following biolistic
transfer into either superficial (skin) or internal (liver)
tissue in vivo, as shown in Figure 3. Peak BLI activity
was observed at the 2d time-point following biolistic
gene delivery into both tissues, with skin showing much
greater BLI activity than liver at this point. Over time,
however, BLI activity in liver was sustained much longer
than that seen in skin. For example, relatively strong
BLI activity persisted through 8d after gene transfer into
liver, whereas BLI activity in skin was nearly undetect-
able by the 8d time-point. BLI activity remained rela-
tively stable in the liver between 4-8d following gene
transfer, and then began to steadily decline over the
next week (Figure 3G). The last time-point measured in
these experiments was 13d post-delivery, and there was
still a small but measurable amount of BLI activity pre-
sent in the liver group. These results show that while
biolistic gene transfer was effective for both liver and
skin, the dynamic features of reporter gene expression
in these two different tissues varied over time.
To determine the depth of gold microcarrier penetra-
tion following bombardment of mouse tissue, we per-
formed histological assessments of abdominal skin 3d
following biolistic gene transfer. In these experiments, we
used pCMV-bGAL reporter plasmid (DLR = 10) to facili-
tate observation of reporter gene activity in histological
sections. The gold microcarriers were readily observed in
histological sections (Figure 4, arrows). Many of them
were found in the outermost layer of skin (epidermis),
but there were clearly clusters of these particles found in
Figure 1 Luciferase expression in transfected cells in culture . (A&C) HEK 293 and (B&D) mouse ES cells transfected using either
lipofectamine 2000 (A&B) or the Helios Gene Gun (C&D). The top row in all sets of plates shown did not receive the luciferin substrate whereas
it was provided to all wells in the bottom row of each plate shown. The leftmost column of each plate contained mock-transfected cells. The
middle column was transfected with pNcx1-LUC, and the rightmost column of each plate was transfected with pCMV-LUC.
Xia et al. BMC Biotechnology 2011, 11:62
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Figure 2 Evaluation of DNA-Loading ratio (DLR). (A) Picture of ethidium bromide-stained agarose gel showing plasmid DNA-gold microcarrier
coupling. The amount of microcarriers calculated to contain 100 ng of plasmid DNA was loaded per lane. Lanes: M, marker (1 Kb ladder; P,
plasmid DNA (pCMV-LUC) alone; 0, 4, 10, 25 refer to DLRs for the respective lanes indicated. (B) Luciferase activity in mouse skin following
biolistic transfer of pCMV-LUC at different DLRs. BLI was performed daily for four days after gene delivery (n = 6). (C-F) Representative pictures
from different DLRs one day after biolistic gene transfer.
Xia et al. BMC Biotechnology 2011, 11:62
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deeper layers. Most of these particles were found
approximately 100 μm from the surface of the skin,
though some were observed as deep as 200-300 μm from
the surface. In contrast, reporter gene activity, as visua-
lized by blue XGAL staining, was mainly found near the
surface of skin, though patches of cells expressing bGAL
were seen as deep as ~150 μm from the skin surface (Fig-
ure 4, arrowheads). These results indicate that biolistic
gene transfer was effective at or near the tissue surface
under the conditions employed in these experiments.
Figure 3 Comparison of BLI following biolistic reporter gene transfer into mouse liver (A-C) or skin (D-F). Representative mice are shown
at day 2 (A and D), 4 (B and E) and 8 for (C and F) following biolistic gene transfer. In each panel, the mouse on the left was transfected with
gold microcarriers alone, and the mouse on the right was transfected with gold microcarriers conjugated with pCMV-LUC (DLR = 10).
Quantitative assessment of these data is shown in panel G.
Xia et al. BMC Biotechnology 2011, 11:62
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Discussion
In the present study, we have shown that different types
of tissues display differential kinetics of transgene expres-
sion following physical gene transfer in vivo. We evalu-
ated biolistic gene transfer in external (skin) and internal
(liver) tissue. In each case, we were able to effectively
monitor and quantify reporter gene expression using BLI.
The main advantage of this approach is that expression
of the gene transferred could be evaluated repeatedly in
the same animals over a period of several days using
non-invasive imaging (BLI) methods. Thus, this strategy
requires fewer animals, reduces variability inherent in
comparing different animals, and is more economical
both in terms of time and money compared with more
traditional approaches for analysis of gene therapy meth-
ods because fewer tissue samples need to be processed
for analysis. Of the tissue types evaluated, decline in
transgene expression was most rapid in the skin (3-4d)
and most stable in the liver (10-14d). Thus, the principal
finding of this study is that transgene expression kinetics
are highly tissue-dependent.
Biolistic gene transfer methods are standard for plants,
but relatively fewer studies have explored this method of
gene transfer in animals. One of the key parameters that
we initially evaluated was the DLR, which represents the
amount of DNA used for coupling to a set amount of
gold microcarriers. We analyzed various DLRs over a
range recommended by the manufacturer of the Helios
gene gun. Despite clear differences in DNA-gold cou-
pling as evidenced by our gel electrophoresis results,
there was surprisingly little difference in transfer effi-
ciency in vivo using DLRs of 4, 10, or 25 (Figure 2). A
likely explanation for these results is that the gold
microcarriers became saturated with bound plasmid
DNA when DLRs of 4 or higher were used, though
higher order complex formation resulting in clumping
of the microcarriers was observed when DLR was raised
to 25. Such clumping can be problematic in that it
makes it difficult to apply a uniform coating of the dis-
charge cartridges, potentially leading to inconsistent
results. Hence, we chose the next highest DLR of 10 for
our experiments to avoid this potential problem. These
findings are consistent with previous reports [31] and
with preliminary studies in our laboratory where we
found that DLRs of 2 or lower appeared to produce less
reporter gene expression compared to DLRs of 4 or
higher (not shown). Conversely, using DLRs greater
than 10 is probably not recommended because most of
the DNA used will be uncoupled or bound up in higher
order complexes resulting in clumping. Therefore, the
optimal DLR appears to be in the range of 4-10 when
using conditions employed in the present study.
Figure 4 Identification of transfected cells in vivo following biolistic delivery of gold-coupled pCMV-bGal into mouse skin. (A-C) Low-
magnification (20X objective; scale bar, 100 μm) and (D-F) Higher-magnification (40X objective; scale bar, 60 μm) views of transverse sections of
mouse skin collected three days after biolistic gene transfer. The sections were stained with XGAL (blue) and eosin (pink). Examples of
microcarriers are indicated by arrows, and transfected cells were identified by blue XGAL staining (arrowheads).
Xia et al. BMC Biotechnology 2011, 11:62
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Helium pressures used in our study varied between
200-400 psi. Although not systematically evaluated here,
we found that pressures of 300-400 psi were well-toler-
ated in skin. Other studies have used even higher pres-
sures (500 psi) for biolistic-mediated gene “vaccinations”
in skin and also observed relatively little tissue damage
[33,40,41]. Maximum recommended helium pressure for
the Bio Rad Helios gene gun is 600 psi. It is anticipated
that “tough” tissues such as skin and muscle can tolerate
pressures approaching this maximum, but that “soft”
internal tissues may not. Consequently, we used lower
helium pressure (200 psi) for gene transfer to liver, which
is similar to what was used in a previous study (250 psi)
to deliver the DNA element regulating cytochrome P450
2B1 [32,42]. We were reluctant to try higher pressures in
liver for fear of causing serious tissue damage, and there
did not appear to be a need to do so anyway because
expression in liver was fairly robust under the conditions
utilized here. In fact, expression persisted in liver for sev-
eral days beyond that observed in the skin. The reason
for this observation is not clear, but may be due in part
to relatively high turnover of epidermis and/or differen-
tial nuclease activities in the two tissues. Indeed, histolo-
gical assessments revealed that most of the microcarriers
were localized to the epidermis following biolistic trans-
fer to skin, with a maximum penetration of not more
than a few hundred microns representing approximately
20-30 cell layers from the surface even when employing
the highest helium pressure (400 psi) used in this study.
Taken together, these results suggest that biolistic gene
transfer conditions need to be optimized for each differ-
ent type of tissue targeted.
Study Limitations and Future Directions
This investigation was limited to two target tissues in
vivo: skin and liver. To compare expression from biolis-
tic-delivered reporter genes, we shot the same CMV-
LUC gold “bullets” into these tissues and compared the
resulting responses over time in vivo using BLI. An
advantage of using the CMV-LUC reporter is that it
produces strong LUC activity that is readily measured
using BLI. This appears to work particularly well for
short-term transient expression, and is consistent with
earlier work showing that this promoter is strongly
expressed in mouse liver following transfection in vivo
[43]. On the other hand, the CMV promoter/enhancer
has limited and questionable utility for longer-term sus-
tained transgene expression applications. Even though
we did not use a viral vector, the presence of the strong
viral enhancer/promoter is still a potential concern. It is
well known, for example, that CMV and other strong
viral promoter are typically silenced by host methylation
mechanisms once they integrate into genomic DNA
[44,45]. The site of integration can also be problematic
in some cases such as those where nearby proto-onco-
genes get activated as a result [14,15]. Future studies
will be developed to investigate tissue-specific promoters
tailored to the relevant target tissues. The present study
focused on short-term transient expression, but future
studies could evaluate more sustained expression over
time for various gene therapy strategies. The use of
homologous human sequences and tissue-specific non-
viral enhancer/promoter elements could be directly
applied using biolistic approaches. BLI should prove
useful for continued evaluation of these approaches in
near real-time in vivo.
Conclusions
We have shown that biolistic gene transfer can be effi-
ciently optimized in different tissues using non-invasive
BLI to monitor expression in the same animals repeat-
edly over time in vivo. Of the representative tissue types
evaluated, expression peaked within 2-3 days for both,
but declined most rapidly in the skin (3-4 days) com-
pared to liver (10-14 days). Thus, tissue-specific expres-
sion kinetics should be an important consideration in
the design of effective gene therapies using physical
gene transfer techniques, which may serve as potentially
useful gene delivery strategies compared with existing
viral-based approaches. Biolistic gene transfer methods
appear to offer an attractive, safe, and effective alterna-
tive to viral vectors for gene therapeutic strategies that
can be directly applied in the clinic to treat a wide vari-
ety of human ailments. So far, biolistic gene transfer
applications in the clinical setting have been primarily
focused on transfection of cells in culture which are
then transplanted to the patient [46-49]. A more recent
study [50] directly targeted external tissues such as epi-
dermis for vaccination applications, and it is anticipated
that there will be more of these types of applications
developing for biolistic gene transfer in the future. The
BLI-based assessment strategy described here should
facilitate optimization of biolistic conditions for different
tissue types in the pre-clinical setting, thereby providing
an efficient means of pre-evaluation of in vivo efficacy
in animal models prior to human trials.
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